
orlyvardeny
@orlyvardeny
ID: 1242860768527294465
25-03-2020 17:08:02
231 Tweet
187 Followers
211 Following

Out now in JACC Journals! Our study showing that finerenone reduces the risk of new-onset AF by ~20% in high-risk CKM patients.📉✨ jacc.org/doi/10.1016/j.… Grateful to my co-authors & mentors Muthu Vaduganathan and scottdavidsolomon for their support! #CardioTwitter #CKM #AFib




“GDMT during and after Acute HF hospitalization” Dra Orly Vardeny orlyvardeny 🇺🇸 Segundo día del Congreso de Falla Cardiaca #CIFACAH2025 En Lima, Perú 🇵🇪 HFSA SIAC American College of Cardiology Paola Morejón Barragán SOPECARD Victor Rossel Gonzalo Perez Bernardita González, MD Guillermina Esperon


HFA Eugene Braunwald Lecture by Dr. Lynne Stevenson — celebrating her groundbreaking contributions and lasting impact on the world of heart failure. A true pioneer! #HeartFailure2025 Novi Yanti Sari Wilfried Mullens Amr Abdin European Society of Cardiology


#CircHF Simultaneous Publication with #HeartFailure2025 from Senthil Selvaraj, MD, MS, MA & Vishal Rao et al: Late-Life Echocardiographic Effects of the Amyloidogenic p.V142I Transthyretin Variant Read more➡️ahajournals.org/doi/10.1161/CI… #AHAJournals Michel Khouri AHA Science

Super interesting data from Safia Chatur, MD scottdavidsolomon and #FINEARTS-HF: Consistent safety and efficacy of finerenone across the eGFR spectrum in HF, and seems more favorable with respect to safety in lower eGFR compared to spironolactone (TOPCAT)


Manuscript in Journal of Cardiac Failure: onlinejcf.com/article/S1071-… Findings to be confirmed in the ongoing REDEFINE-HF trial. Shelley Zieroth orlyvardeny Andrew J Sauer MD Peder L. Myhre MD, PhD Gianluigi Savarese

Manuscript simultaneously published in Journal of Cardiac Failure : onlinejcf.com/article/S1071-…

HFpEF affects ~4M in the U.S. Once lacking therapies, HFpEF is now seeing rapid progress—with SGLT2i, Ns-MRAs, and GLP-1 RAs offering hope, especially for the obesity phenotype. (link.springer.com/article/10.100…). #HREV Josephine Harrington, MD Marc Bonaca MD MPH Andrew J Sauer MD orlyvardeny Mario Enrico Canonico

FINEARTS-HF is the 2nd large RCT to include patients with #HFimpEF. Out now🚨 our new JAMA Cardiology analysis shows that finerenone confers benefit in this group, despite their persistent risk of adverse outcomes jamanetwork.com/journals/jamac… Muthu Vaduganathan scottdavidsolomon orlyvardeny


Patients with heart failure and HFimpEF remain at high risk for cardiovascular events, but finerenone consistently reduces this risk without significant adverse effects. ja.ma/4jjmY0T orlyvardeny Muthu Vaduganathan Sanjiv J. Shah, MD Adriaan Voors clara saldarriaga


Finerenone in Heart Failure with Improved Ejection Fraction in #FINEARTSHF led by Maria A. Pabón, MD in JAMA Cardiology jamanetwork.com/journals/jamac…


📣Calling all #AHFTC Fellows! Circ: Heart Failure is proud to launch a free educational webinar series for current or past AHFTC fellows. 📍8 live virtual sessions, 1 in-person event 📍New topic each session 📅Start Date: August 13, 2025 🔗Learn More: ahajournals.org/circheartfailu…






Congrats to @AnkeetBhattMD and the KP-VACCINATE team! ~4 million adults randomized in 4 weeks—the largest RCT ever fully embedded in a LHS. Testing CV-focused vs. usual care messaging to improve flu vaccination. Results soon. (sciencedirect.com/science/articl…). Tor Biering-Sørensen, MD, MSc, MPH, PhD Muthu Vaduganathan